Increased cannabinoid CB1 receptor binding and activation of GTP‐binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP‐treated marmosets
Authors:
- I Lastres-BeckerI Lastres-Becker
- M CebeiraMCM Cebeira
- M L De CeballosM L De Ceballos
- B Y ZengBZB Y Zeng
- P JennerPJP Jenner
- J A RamosJRJ A Ramos
- J J Fernández-RuizJFJ J Fernández-Ruiz
- 20 December 2001
- journal article
- research article
- Published by Wiley in European Journal of Neuroscience
- Vol. 14 (11) , 1827-1832
Abstract
Recent evidence obtained in rat models of Parkinson's disease showed that the density of cannabinoid CB1 receptors and their endogenous ligands increase in basal ganglia. However, no data exists from post‐mortem brain of humans affected by Parkinson's disease or from primate models of the disorder. In the present study, we examined CB1 receptor binding and the magnitude of the stimulation by WIN55,212‐2, a specific CB1 receptor agonist, of [35S]GTPγS binding to membrane fractions from the basal ganglia of patients affected by Parkinson's disease. In Parkinson's disease, WIN55,212‐2‐stimulated [35S]GTPγS binding in the caudate nucleus, putamen, lateral globus pallidus and substantia nigra was increased, thus indicating a more effective activation of GTP‐binding protein‐coupled signalling mechanisms via CB1 receptors. This was accompanied by an increase in CB1 receptor binding in the caudate nucleus and the putamen, although no changes were observed in the lateral globus pallidus and the substantia nigra. Because Parkinson's disease patients had been chronically treated with l‐DOPA, brains were studied from normal common marmosets and 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)‐treated animals with and without chronic L‐DOPA treatment. MPTP‐lesioned marmosets had increased CB1 receptor binding in the caudate nucleus and the putamen compared to control marmosets, as well as increased stimulation of [35S]GTPγS binding by WIN55,212‐2. However, following l‐DOPA treatment these parameters returned towards control values. The results indicate that a nigro‐striatal lesion is associated with an increase in CB1 receptors in the basal ganglia in humans and nonhuman primates and that this increase could be reversed by chronic l‐DOPA therapy. The data suggest that CB1 receptor blockade might be useful as an adjuvant for the treatment of parkinsonian motor symptoms.Keywords
This publication has 39 references indexed in Scilit:
- Striatal Cannabinoid CB1 Receptor mRNA Expression Is Decreased in the Reserpine-Treated Rat Model of Parkinson's DiseaseExperimental Neurology, 2001
- Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's diseaseThe FASEB Journal, 2000
- Brain Cannabinoid Systems as Targets for the Therapy of Neurological DisordersNeurobiology of Disease, 1998
- Adjuncts to dopamine replacement: A pragmatic approach to reducing the problem of dyskinesia in Parkinson's diseaseMovement Disorders, 1998
- Chronic L‐DOPA administration induces dyskinesias in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐treated common marmoset (Callithrix jacchus)Movement Disorders, 1995
- Time-course of the effects of anandamide, the putative endogenous cannabinoid receptor ligand, on extrapyramidal functionBrain Research, 1995
- The cannabinoid agonists WIN 55,212-2 and CP 55,940 attenuate rotational behavior induced by a dopamine D1 but not a D2 agonist in rats with unilateral lesions of the nigrostriatal pathwayBrain Research, 1995
- The endogenous cannabinoid receptor ligand, anandamide, inhibits the motor behavior: role of nigrostriatal dopaminergic neuronsLife Sciences, 1995
- Glutamatergic regulation of cannabinoid receptor gene expression in the caudate-putamenEuropean Journal of Pharmacology: Molecular Pharmacology, 1994
- Dopaminergic Regulation of Cannabinoid Receptor mRNA Levels in the Rat Caudate‐Plitamen: An In Situ Hybridization StudyJournal of Neurochemistry, 1993